Somatuline: Advanced Treatment Methods For Neuroendocrine Tumors
Lanreotide, sold under brands such as Somatuline, is a medication used to treat symptoms caused by acromegaly and neuroendocrine tumors (most notably carcinoid syndrome).
It is a long-acting somatostatin analogue similar to octreotide.
Breakthrough In The Treatment Of Neuroendocrine Tumors
Neuroendocrine tumors are usually diagnosed in late stages and have been difficult to treat due to their unpredictable growth patterns and resistance to traditional cancer therapies.
For patients with neuroendocrine tumors, somatuline is also a great boon.
These types of tumors are usually invasive and difficult to treat.
Lanreotide not only slows down the growth rate of tumors, but also to some extent alleviates a series of symptoms caused by excessive hormone secretion by tumors, such as diarrhea and flushing.
In multiple clinical trials, many patients have experienced a reduction in tumor volume and effective delay in disease progression after receiving Somatuline treatment.
Somatuline: Innovative Treatments To Improve Patients’ Quality Of Life
Somatuline, as a long-acting hormone growth releasing dye (SRIF), has a unique and efficient mechanism of action.
It can simulate the function of human somatostatin and effectively inhibit the release of growth hormone and various growth promoting factors by binding to specific receptors, thereby exerting a significant inhibitory effect on the growth, proliferation, and spread of tumor cells.
It reduces tumor swelling by inhibiting tumor cell growth hormone and other factors, and effectively prolongs the patient’s lifespan while relieving symptoms.
Somatuline: Convenient subcutaneous injection
There are two dosage forms of Lanrui Peptide: one is the sustained-release dosage form (marketed as “Somatuline LA”), which is injected intramuscularly every 10 or 14 days, and the other is the extended-release dosage form (marketed as “Somatuline Autogel” in the UK and “Somatuline Depot” in the US), which is injected subcutaneously once a month.
Greatly reducing the frequency of treatment for patients.
Future Prospects: Bringing Hope To Cancer Patients
The approval of somatuline has brought new treatment options for neuroendocrine patients worldwide, especially for those who cannot receive tumor surgery or traditional treatment. It provides a more effective and convenient treatment pathway.
Summary
The approval of tomatine for a market not only provides more efficient and convenient treatment options for neuroendocrine patients but also injects new impetus into the innovative development of global cancer treatment.
As a long-acting growth hormone-releasing hormone, Lanreotide provides patients with long-lasting resistance to longer-lasting anti-tumour treatments, bringing new hope to cancer treatment.
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to contact us to buy Somatuline Lanreotide.
Information from HK DengYueMedicine, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
